

**PRELIMINARY SCIENTIFIC PROGRAM  
As of 8 September 2019**

PLENARY SESSION	PARALLEL SESSION	ORAL PRESENTATION SESSION	INDUSTRY SESSION	BREAK
-----------------	------------------	---------------------------	------------------	-------

**Wednesday, 19 February 2020**

HALL	A	B	C	D
14:30-16:00	PARALLEL INDUSTRY SESSION	PARALLEL INDUSTRY SESSION	PARALLEL INDUSTRY SESSION	PARALLEL INDUSTRY SESSION
16:15-17:45	PARALLEL INDUSTRY SESSION	PARALLEL INDUSTRY SESSION	PARALLEL INDUSTRY SESSION	PARALLEL INDUSTRY SESSION
HALL				
18:00-19:00	OPENING CEREMONY			
	Moshe Phillip - Opening Remarks			
	Keynote speaker – Jay Skyler - The Evolution of Diabetes Technology			
19:00-20:00	NETWORKING RECEPTION (In the Exhibition Area)			

## Thursday, 20 February 2020

<b>HALL</b>						
<b>08:30-10:00</b>	<b>PLENARY SESSION (1) HYPERGLYCEMIA &amp; COGNITIVE FUNCTION IN DIABETES</b>					
	<p><b>Nelly Mauras</b> – The brain as a target of diabetes complications in children</p> <p><b>Elisabeth Selvin</b> – TBC</p>					
<b>10:00-10:30</b>	<b>COFFEE BREAK, EXHIBITION, POSTERS AND E- POSTER DISCUSSIONS</b>					
<b>HALL</b>						
<b>10:30-12:00</b>	<b>PLENARY INDUSTRY SYMPOSIUM</b>					
<b>12:00-13:00</b>	<b>LUNCH BREAK, EXHIBITION, POSTERS AND E- POSTERS, INTERNATIONAL FAIR OF NEW TECHNOLOGIES IN DIABETES</b>					
<b>HALL</b>	<b>A</b>	<b>B</b>	<b>C</b>	<b>D</b>	<b>E</b>	<b>F</b>
<b>13:00-14:30</b>	<b>PARALLEL SESSION (1) EMERGING THERAPIES FOR TYPE 2 DIABETES</b>	<b>PARALLEL SESSION (2) SCREEING &amp; EARLY INTERVENTION IN TYPE 1 DIABETES</b>	<b>PARALLEL SESSION (3) DECISION SUPPORT SYSTEMS IN DIABETES</b>	<b>JDRF PARALLEL SESSION (4)</b>	<b>PARALLEL INDUSTRY SESSION</b>	<b>PARALLEL INDUSTRY SESSION</b>
	<p><b>Antonio Ceriello</b> – Glucose variability as a risk factor for complications in diabetes</p> <p><b>Julio Rosenstock</b> – What is coming in the treatment of T2DM: time to move on with early simultaneous therapies</p> <p><b>Richard Bergenstal</b> – Why is there a resurgence in</p>	<p><b>Marian Rewers</b> – General population screening for T1D</p> <p><b>Olga Kordonouri</b> – Killing two birds with one stone: should diabetes screening be combined?</p> <p><b>Desmond Schatz</b> – Efficacy of low dose antithymocyte globulin in</p>	<p><b>Bruce Bode</b> – Use of decision support systems in the hospital to manage glucose</p> <p><b>Sean Sullivan</b> - Implementation of clinical decision support tools</p> <p><b>Boris Kovatchev</b> – Biosensing, Diabetes Data</p>	<b>TBD</b>		

	diabetes complications and what can we do about it? <b>David Rodbard</b> - Insulin - A century of progress leading to the ultra long-acting Insulin analogs	new-onset type 1 diabetes: Implication for Prevention <b>Peter Gottlieb</b> – Methyldopa for early intervention in Type 1 diabetes	Science and decision support			
<b>14:30-15:00</b>	<b>COFFEE BREAK, EXHIBITION, POSTERS AND E- POSTERS, INTERNATIONAL FAIR OF NEW TECHNOLOGIES IN DIABETES</b>					
<b>HALL</b>						
<b>15:00-16:30</b>	<b>PLENARY INDUSTRY SYMPOSIUM</b>					
<b>16:30-16:40</b>	<b>SHORT BREAK</b>					

<b>HALL</b>	<b>A</b>	<b>B</b>	<b>C</b>	<b>D</b>	<b>E</b>	<b>F</b>
<b>16:40-18:00</b>	<b>PARALLEL SESSION (5) SOCIAL MEDIA - WHAT WORKS AND WHAT DOES NOT</b>	<b>PARALLEL SESSION (6) ADJUNCTIVE THERAPIES FOR TYPE 1 DIABETES</b>	<b>PARALLEL SESSION (7) CLOSED-LOOP - UPDATE</b>	<b>PARALLEL SESSION (8) DIABETES, THECHNOLOGY AND PREGANANCY</b>	<b>ORAL PRESENTATION SESSION 1</b>	<b>ORAL PRESENTATION SESSION 2</b>
	<b>Chris Aldred aka The Grumpy Pumper and Renza Scibilia</b> - Do you think you should have looked after yourself better? - Language and Complications <b>Claire Reidy</b> - structured peer support - benefits and pitfalls <b>Partha Kar</b> - Social media & technology: Dark Arts or a welcome disrupter?	Debate on SGLT2 for T1D: <b>Thomas Danne</b> - Pro <b>Stephanie Amiel</b> - Con <b>Thomas Dejgaard</b> - GLP-1 and DPP-IV in type 1 diabetes <b>Jennifer Sherr</b> - Pramlintide and metformin in type 1 diabetes	<b>Eyal Dassau</b> - First clinical report of on-body artificial pancreas in pediatric and outpatient extended use of a mobile app <b>Francis Doyle</b> - Automated adaptive control in the outpatient setting - Interim results of the iDCL Harvard study <b>Roman Hovorka</b> - A new closed loop system from Cambridge: CamAPS-FX	<b>Yariv Yogev</b> - Controversies in the treatment of diabetes in pregnancy- how to define well controlled? <b>Nebojsa Lalic</b> – Insulin pump treatment and insulin sensitivity during pregnancy: gestational vs. pre-existing diabetes <b>Helen Murphy</b> - The use of automated insulin		

	<b>Neal Kaufman</b> – Digital therapeutics using social media for people with diabetes		<b>Boris Kovatchev</b> - Latest artificial pancreas (AP) developments	delivery (AID) in Type 1 Diabetes Pregnancy <b>Eyal Sheiner</b> - Maternal and neonatal long- term outcome after pregnancy complicated with diabetes		
--	--	--	---	---	--	--

## Friday, 21 February 2019

<b>HALL</b>						
<b>08:00-08:50</b>	<b>PLENARY INDUSTRY MORNING SYMPOSIUM</b>					
<b>08:50-09:00</b>	<b>SHORT BREAK</b>					
<b>HALL</b>	<b>A</b>	<b>B</b>	<b>C</b>	<b>D</b>	<b>E</b>	<b>F</b>
<b>09:00-10:00</b>	<b>PARALLEL SESSION (9) ENABLERS AND BARRIERS IN MANAGING DIABETES</b>	<b>PARALLEL SESSION (10) WHERE DO WE GO WITH SMBG AND CGM?</b>	<b>PARALLEL SESSION (11) SGLT2 AS ADJUNCTIVE AGENT IN TREATING TYPE 1 DIABETES</b>	<b>ORAL PRESENTATION SESSION 3</b>	<b>PARALLEL INDUSTRY SESSION</b>	<b>PARALLEL INDUSTRY SESSION</b>
	<p><b>Mette Due-Christensen</b> - Psychological issues at diagnosis of type 1 diabetes</p> <p><b>Frank Snoek</b> – Fear of hypoglycemia</p> <p><b>Frans Pouwer</b> - impact of hypoglycaemia on patient reported outcomes</p>	<p><b>Guido Freckmann</b> - Which standards do we need for continuous glucose monitoring (CGM)?</p> <p><b>Irl Hirsch</b> – Who will use SMBG in five years from now?</p> <p><b>Lutz Heinemann</b> – Diabetes technology and trash</p>	<p><b>Satish Garg</b> - SGLT inhibitors for Type 1 diabetes - Introduction</p> <p><b>Chantal Mathieu</b> – SGLT2 in type 1 diabetes – Efficacy</p> <p><b>Thomas Danne</b> - Experience with risk mitigation using SGLT-inhibitors in Type 1 diabetes</p>			
<b>10:00-10:30</b>	<b>COFFEE BREAK, EXHIBITION, POSTERS AND E- POSTER DISCUSSIONS</b>					
<b>HALL</b>						
<b>10:30-12:00</b>	<b>PLENARY INDUSTRY SYMPOSIUM</b>					
<b>12:00-13:00</b>	<b>LUNCH BREAK, EXHIBITION, POSTERS AND E- POSTERS, INTERNATIONAL FAIR OF NEW TECHNOLOGIES IN DIABETES</b>					

<b>HALL</b>	
<b>13:00-14:30</b>	<b>PLENARY SESSION (2) ATTD YEARBOOK 2019</b>
<b>14:30-15:00</b>	<b>COFFEE BREAK, EXHIBITION, POSTERS AND E- POSTERS</b>
<b>HALL</b>	
<b>15:00-16:30</b>	<b>PLENARY INDUSTRY SYMPOSIUM</b>
<b>16:30-16:40</b>	<b>SHORT BREAK</b>

<b>HALL</b>	<b>A</b>	<b>B</b>	<b>C</b>	<b>D</b>	<b>E</b>	<b>F</b>
<b>16:40-18:00</b>	<b>PARALLEL SESSION (12) THE ARTIFICIAL PANCREAS IN DAILY PRACTICE: HOW TO SELECT AND TRAIN THE CANDIDATES?</b>	<b>PARALLEL SESSION (13) REAL-WORLD DATA</b>	<b>PARALLEL SESSION (14) ISPAD SESSION UNMET TECHNOLOGY NEEDS IN PEDIATRIC DIABETES</b>	<b>PARALLEL SESSION (15) EXERCISE MANAGEMENT: FROM TOOLS TO TECHNIQUES</b>	<b>PARALLEL INDUSTRY SESSION</b>	<b>PARALLEL INDUSTRY SESSION</b>
	<p><b>Rich Bergenstal</b> - Successes and failures with 670G</p> <p><b>Charlotte Boughton</b> - Training and patient selection for the Artificial Pancreas</p> <p><b>Katharine Barnard</b> - What do the patients think of Artificial Pancreas?</p>	<p><b>David Klonoff</b> - Real-World evidence in clinical trials</p> <p><b>Irl Hirsch</b> - A Real-World look of time in range (TIR) and glucose management indicator (GMI)</p> <p><b>Roy Beck</b> - Time in range and diabetes complications</p> <p><b>Lori Laffel</b> - Approaches to increasing glucose</p>	<p><b>Andrea Scaramuzza</b> - Introduction</p> <p><b>Roque Cardona Hernandez</b> - Unmet technology needs in minority people in Europe</p> <p><b>Asma Deeb</b> - Unmet technology needs in Arabic region, Africa and Asia</p> <p><b>Priya Prahalad</b> - Unmet technology needs in minority people in North and South America</p>	<p><b>Michael Riddell</b> - Physiologic and technologic challenges of exercise management in diabetes</p> <p><b>Eyal Dassau</b> - Identifying and classifying physical activity for robust automatic insulin delivery (AID) systems</p> <p><b>Peter Jacobs</b> - Using machine learning to predict glucose changes during aerobic, anaerobic and</p>		

		time-in-range in the pediatric age group	<b>Q&amp;A</b> <b>David Maahs</b> - Conclusions	mixed forms of exercise in patients with type 1 diabetes <b>Marc Breton</b> - Clinical trial results of an artificial pancreas (AP) System that anticipates physical activity patterns in type 1 diabetes		
--	--	--	---	--	--	--

**Saturday, 22 February 2020**

HALL	A	B	C	D	E
08:30-10:00	<b>PARALLEL SESSION (16) TECHNOLOGY IN REAL LIFE</b>	<b>PARALLEL SESSSION (17) UPDATES ON NAFLD/NASH</b>	<b>PARALLEL SESSION (18) TECHFAIR PRESENTATIONS</b>	<b>ORAL PRESENTATION SESSION 4</b>	<b>ORAL PRESENTATION SESSION 5</b>
	<p><b>Katharine Barnard</b> – Onboarding and support needs for people with diabetes (PWD) and health care providers (HCPs)</p> <p><b>Stuart Weinzimer</b> – Human factor in closed-loop</p> <p><b>Nataša Bratina</b> – Closed-loop in school</p> <p><b>TBC</b> - Safety and effectiveness of on market diabetes devices</p>	<p><b>Kavita Garg</b> - Introduction and Emerging Imaging Technologies for NAFLD/NASH</p> <p><b>Christophe De Block</b> - Prevention and Pharmacological Interventions in NAFLD/NASH</p> <p><b>TBD</b> -</p> <p><b>Q and A</b></p>	<p>Presentations of outstanding TechFair exhibitors</p>		
10:00-10:30	<b>COFFEE BREAK, EXHIBITION, POSTERS AND E- POSTERS, INTERNATIONAL FAIR OF NEW TECHNOLOGIES IN DIABETES</b>				

HALL	A	B	C	D	E
10:30-12:00	<b>PARALLEL SESSION (19) ULTRA-RAPID INSULIN ANALOGUES</b>	<b>PARALLEL SESSION (20) HYPOGLYCEMIA AND THE BRAIN</b>	<b>PARALLEL SESSION (21) NUTRITION AND FOOD TECHNOLOGIES</b>	<b>PARALLEL SESSION (22) CGM, PUMPS AND CLOSED-LOOP</b>	<b>ORAL PRESENTATION SESSION 6</b>
	<p><b>Bruce Bode</b> – Ultra fast-acting insulins in closed-loop systems</p> <p><b>Steven Edelman</b> – Afrezza – How to use it and when</p>	<p><b>Pratik Choudhary</b> - Using neuroimaging to understand mechanisms of hypoglycaemia unawareness</p> <p><b>Simon Heller</b> - Understanding the impact of hypoglycaemia:</p>	<p><b>Elena Hernando</b> - Web-based support system for gestational diabetes and weight-loss interventions (TBC)</p> <p><b>Piotr Ladyzynski</b> - Technologies and systems</p>	<p><b>Amy Criego</b> – Continuous glucose monitoring (CGM) as initial diabetes technology</p> <p><b>Gregory Forlenza</b> - Clinical implementation and</p>	



	<p><b>Kirsten Noergaard</b> – FiAsp Insulin – Evidence and experience in using it</p> <p><b>Tim Heise</b> - How early is URLi (Ultra Rapid Lispro)?</p>	<p>severe, non-severe and sensor detected hypoglycemia</p> <p><b>Stuart Weinzimer</b> – The role of subcutaneous glucagon</p> <p><b>Jennifer Sherr</b> - Nasal glucagon: a novel rescue option for SH</p>	<p>for meal counting and estimating prandial insulin dose</p> <p><b>Revital Nimri</b> - Cracking the meal challenge – insight from closed-loop studies</p>	<p>utilization of hybrid closed-loop technology</p> <p><b>Klemen Dovc</b> – Closed-loop and physical activity</p> <p><b>Laurel Messer</b> - Skin in the Game: Preserving skin integrity for sustained device use</p>	
--	---	---	--	--	--

<b>HALL</b>	
<b>12:00-13:00</b>	<b>PLENARY SESSION (3) GLIMPSE TO THE FUTURE</b>
	<p><b>Walter Pories</b> – Long-term outcome of metabolic surgery</p> <p><b>Jay Skyler</b> – Towards the cure of T1D</p> <p><b>Moshe Phillip</b> – Digital diabetes</p>
<b>13:00-13:05</b>	<b>CLOSING REMARKS AND FAREWELL</b>
<b>13:05-13:45</b>	<b>FAREWELL REFRESHMENTS</b>